Heron Therapeuti (HRTX) - Total Assets
Based on the latest financial reports, Heron Therapeuti (HRTX) holds total assets worth $248.95 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HRTX net assets for net asset value and shareholders' equity analysis.
Heron Therapeuti - Total Assets Trend (1987–2024)
This chart illustrates how Heron Therapeuti's total assets have evolved over time, based on quarterly financial data.
Heron Therapeuti - Asset Composition Analysis
Current Asset Composition (December 2024)
Heron Therapeuti's total assets of $248.95 Million consist of 89.7% current assets and 10.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.1% |
| Accounts Receivable | $78.88 Million | 33.8% |
| Inventory | $53.16 Million | 22.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1987–2024)
This chart illustrates how Heron Therapeuti's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Heron Therapeuti (HRTX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Heron Therapeuti's current assets represent 89.7% of total assets in 2024, an increase from 78.6% in 1987.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2024, down from 75.7% in 1987.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1987.
- Asset Diversification: The largest asset category is accounts receivable at 33.8% of total assets.
Heron Therapeuti Competitors by Total Assets
Key competitors of Heron Therapeuti based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Heron Therapeuti - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.56 | 2.28 | 3.07 |
| Quick Ratio | 1.78 | 1.74 | 2.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $139.69 Million | $109.64 Million | $211.69 Million |
Heron Therapeuti - Advanced Valuation Insights
This section examines the relationship between Heron Therapeuti's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.16 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 4.8% |
| Total Assets | $233.15 Million |
| Market Capitalization | $210.87 Million USD |
Valuation Analysis
Near Book Valuation: The market values Heron Therapeuti's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Heron Therapeuti's assets grew by 4.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Heron Therapeuti (1987–2024)
The table below shows the annual total assets of Heron Therapeuti from 1987 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $233.15 Million | +4.78% |
| 2023-12-31 | $222.51 Million | -11.33% |
| 2022-12-31 | $250.95 Million | -17.91% |
| 2021-12-31 | $305.71 Million | -13.53% |
| 2020-12-31 | $353.56 Million | -31.05% |
| 2019-12-31 | $512.78 Million | +10.95% |
| 2018-12-31 | $462.18 Million | +97.25% |
| 2017-12-31 | $234.31 Million | +247.21% |
| 2016-12-31 | $67.48 Million | -51.05% |
| 2015-12-31 | $137.84 Million | +79.76% |
| 2014-12-31 | $76.68 Million | +0.98% |
| 2013-12-31 | $75.94 Million | +35.67% |
| 2012-12-31 | $55.97 Million | +187.85% |
| 2011-12-31 | $19.45 Million | +567.98% |
| 2010-12-31 | $2.91 Million | -67.48% |
| 2009-12-31 | $8.95 Million | -24.14% |
| 2008-12-31 | $11.80 Million | -68.06% |
| 2007-12-31 | $36.95 Million | +114.19% |
| 2006-12-31 | $17.25 Million | +92.34% |
| 2005-12-31 | $8.97 Million | -47.28% |
| 2004-12-31 | $17.01 Million | +29.33% |
| 2003-12-31 | $13.15 Million | -26.09% |
| 2002-12-31 | $17.80 Million | -24.28% |
| 2001-12-31 | $23.51 Million | -12.92% |
| 2000-12-31 | $27.00 Million | +14.88% |
| 1999-12-31 | $23.50 Million | +1.73% |
| 1998-12-31 | $23.10 Million | -4.55% |
| 1997-12-31 | $24.20 Million | +31.52% |
| 1996-12-31 | $18.40 Million | -20.35% |
| 1995-12-31 | $23.10 Million | -1.70% |
| 1994-12-31 | $23.50 Million | -3.69% |
| 1993-12-31 | $24.40 Million | -13.78% |
| 1992-12-31 | $28.30 Million | +194.79% |
| 1991-12-31 | $9.60 Million | -17.24% |
| 1990-12-31 | $11.60 Million | -12.12% |
| 1989-12-31 | $13.20 Million | -21.43% |
| 1988-12-31 | $16.80 Million | -20.00% |
| 1987-12-31 | $21.00 Million | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more